Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Unity Biotechnology Inc has a consensus price target of $7.43 based on the ratings of 8 analysts. The high is $10 issued by HC Wainwright & Co. on November 14, 2023. The low is $4 issued by Roth Capital on January 4, 2022. The 3 most-recent analyst ratings were released by Rodman & Renshaw, HC Wainwright & Co., and HC Wainwright & Co. on August 22, 2024, August 8, 2024, and May 15, 2024, respectively. With an average price target of $8 between Rodman & Renshaw, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 446.86% upside for Unity Biotechnology Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Unity Biotechnology (NASDAQ:UBX) was reported by Rodman & Renshaw on August 22, 2024. The analyst firm set a price target for $8.00 expecting UBX to rise to within 12 months (a possible 446.86% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Unity Biotechnology (NASDAQ:UBX) was provided by Rodman & Renshaw, and Unity Biotechnology initiated their buy rating.
The last upgrade for Unity Biotechnology Inc happened on November 16, 2023 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for Unity Biotechnology Inc.
The last downgrade for Unity Biotechnology Inc happened on June 26, 2023 when Wedbush changed their price target from $3 to $2 for Unity Biotechnology Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on August 22, 2024 so you should expect the next rating to be made available sometime around August 22, 2025.
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a initiated with a price target of $0.00 to $8.00. The current price Unity Biotechnology (UBX) is trading at is $1.46, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.